Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Veterinary drug bioequivalence determination

P L Toutain1, G D Koritz

  • 1Unité Associée INRA de Physiopathologie et Toxicologie Expérimentales, Ecole Nationale Vétérinaire de Toulouse, France.

Journal of Veterinary Pharmacology and Therapeutics
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European Network for Optimization of Veterinary Antimicrobial Therapy (ENOVAT) 2025 guidelines for surgical antimicrobial prophylaxis in dogs and cats.

The Journal of small animal practice·2025
Same author

Understanding the rationale for metronidazole use in dogs and cats.

The Journal of small animal practice·2025
Same author

Antimicrobial prophylaxis in companion animal surgery: A scoping review for European Network for Optimization of Antimicrobial Therapy (ENOVAT) guidelines.

Veterinary journal (London, England : 1997)·2024
Same author

A new LC/MS method for specific determination of human systemic exposure to bisphenol A, F and S through their metabolites: Application to cord blood samples.

Environment international·2021
Same author

Authors' Reply to Krebs-Brown et al. Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?"

Clinical pharmacokinetics·2019
Same author

Scabies in an obese patient: How should the ivermectin dosing be adapted?

Medecine et maladies infectieuses·2018

Bioequivalence trials statistically compare drug formulations to ensure interchangeability. If bioavailability parameters differ by 20% or less with 90% confidence, formulations are considered bioequivalent.

Area of Science:

  • Pharmacokinetics and Pharmaceutical Sciences
  • Clinical Trial Design
  • Drug Formulation and Bioavailability

Background:

  • Bioequivalence trials are essential for demonstrating the interchangeability of different drug formulations.
  • The core principle is that similar plasma concentration-time profiles lead to comparable therapeutic effects.
  • Regulatory acceptance hinges on statistical evidence of interchangeability with controlled patient risk.

Purpose of the Study:

  • To review the design and evaluation methodologies of bioequivalence studies.
  • To highlight key scientific considerations in assessing drug product interchangeability.
  • To provide a comprehensive overview of bioequivalence trial principles.

Main Methods:

  • Statistical comparison of pharmacokinetic parameters between two drug formulations.

Related Experiment Videos

  • Assessment of bioavailability, focusing on rate and extent of drug absorption.
  • Application of confidence intervals (typically 90%) to determine the degree of similarity.

    • Main Results:

    • Bioequivalence is generally established when bioavailability parameters (rate and extent) do not differ by more than 20%.
    • A 90% confidence interval is the standard for demonstrating bioequivalence.
    • The plasma time-course is a critical determinant of therapeutic equivalence.

    Conclusions:

    • Bioequivalence trials provide a robust framework for ensuring drug product interchangeability.
    • Understanding the design and evaluation is crucial for regulatory compliance and patient safety.
    • Kinetic endpoints are primary measures for assessing bioequivalence.